1. Reyes-González JM and Vivas-Mejía PE. c-MYC and epithelial ovarian cancer. Front Oncol 2021; 11: 601512.
2.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209-249.
3.
Feeney L, Harley IJ, McCluggage WG, Mullan PB, Beirne JP. Liquid biopsy in ovarian cancer: Catching the silent killer before it strikes. World J Clin Oncol 2020; 11: 868-889.
4.
Panda PK, Mukhopadhyay S, Das DN. Mechanism of autophagic regulation in carcinogenesis and cancer therapeutics. Semin Cell Dev Biol 2015.
5.
Marinkoviæ M, Šprung M, Buljubašiæ M, Novak I. Autophagy modulation in cancer: current knowledge on action and therapy. Oxid Med Cell Longev 2018; 31: 8023821.
6.
Yu Q, Fu W, Fu Y, Ye W, Yan H, Yu Z, et al. BNIP3 as a potential biomarker for the identification of prognosis and diagnosis in solid tumours. Mol Cancer 2023; 22: 143.
7.
Vianello C, Cocetta V, Catanzaro D, Dorn GW, De Milito A, Rizzolio F, et al. Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy. Cell Death Dis 2022; 13: 398.
8.
Colliez F, Gallez B, Jordan BF. Assessing tumor oxygenation for predicting outcome in radiation oncology: a review of studies correlating tumor hypoxic status and outcome in the preclinical and clinical settings. Front Oncol 2017; 7: 10.
9.
Lokuhetty D WVA, Watanabe R. Lyon. WHO Classification of Female Genital Tumors. 5th ed. (IARC) IAfRoC, editor 2020.
10.
Oliveira LRLBd, Horvat N, Andrieu PIC, Panizza PSB, Cerri GG, Viana PCC. Ovarian cancer staging: what the surgeon needs to know. Br J Radiol 2021; 94: 20210091.
11.
De Leo A, Santini D, Ceccarelli C, Santandrea G, Palicelli A, Acquaviva G, et al. What is new on ovarian carcinoma: integrated morphologic and molecular analysis following the new 2020 World Health Organization Classification of Female Genital Tumors. Diagnostics (Basel) 2021; 11: 697.
12.
McCluggage WG, Judge MJ, Clarke BA, Davidson B, Gilks CB, Hollema H, et al. Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Mod Pathol 2015; 28: 1101-1122.
13.
Parra-Herran C, Bassiouny D, Lerner-Ellis J, Olkhov-Mitsel E, Ismiil N, Hogen L, et al. p53, mismatch repair protein, and POLE abnormalities in ovarian clear cell carcinoma: an outcome-based clinicopathologic analysis. Am J Surg Pathol 2019; 43: 1591-1599.
14.
Macher-Goeppinger S, Keith M, Hatiboglu G, Hohenfellner M, Schirmacher P, Roth W, et al. Expression and functional characterization of the BNIP3 protein in renal cell carcinomas. Transl Oncol 2017; 10: 869-875.
15.
Alabiad M, Harb O, Mandour D, Hemeda R, Ahmed RZ, El-Taher A, et al. Prognostic and clinicopathological implications of expression of Beclin-1 and hypoxia-inducible factor 1α in serous ovarian carcinoma: an immunohistochemical study. Pol J Pathol 2021; 72:23-38
16.
Gibson SB. Autophagy in clear cell ovarian cancer, a potential marker for hypoxia and poor prognosis? J Pathol 2012; 228: 434-436.
17.
Kubli DA, Ycaza JE, Gustafsson AB. BNIP3 mediates mitochondrial dysfunction and cell death through Bax and Bak. Biochem J 2007; 405: 407-415.
18.
Drake LE, Springer MZ, Poole LP, Kim CJ, Macleod KF. Expanding perspectives on the significance of mitophagy in cancer. Semin Cancer Biol 2017; 47: 110-124.
19.
Fan W, Zhang Y, Yang X, Liu Z, Wu X, Li L, et al. BNIP3 as a potential target of esculetin for treating ovarian cancer and prognostic biomarker in ovarian cancer patients. Eur J Pharmacol 2025; 999: 177698.
20.
Jia J, Yang X, Zhao Q, Ying F, Cai E, Sun S, et al. BNIP3 contributes to cisplatin-induced apoptosis in ovarian cancer cells. FEBS Open Bio 2020; 10: 1463-1473.
21.
Jia XN, Yin SD, Wei Y, Chen L. MiR-182-5p inhibited proliferation and migration of ovarian cancer cells by targeting BNIP3. Eur Rev Med Pharmacol Sci 2019; 23: 3270–3276.
22.
Bristow N, Burton TR, Henson ES, Ong-Justiniano C, Brown M, Gibson SB. Truncated forms of BNIP3 act as dominant negatives inhibiting hypoxia-induced cell death. Biochim Biophys Acta 2011; 1812: 302-311.
23.
Lee H, Paik SG. Regulation of BNIP3 in normal and cancer cells. Mol Cells 2006; 21: 1-6.
24.
Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist 2004; 9: 10-17.
25.
Zhang J, Ney PA. Role of BNIP3 and NIX in cell death, autophagy, and mitophagy. Cell Death Differ 2009; 16: 939-946.
26.
Mellor HR, Harris AL. The role of the hypoxia-inducible BH3-only proteins BNIP3 and BNIP3L in cancer. Cancer Metastasis Rev 2007; 26: 553-566.
27.
Chen Z, Wu H, Huang S, Li W, Zhang S, Zheng P, et al. Expression of BNIP3 and its correlations to hypoxia-induced autophagy and clinicopathological features in salivary adenoid cystic carcinoma. CA Biom 2015; 15: 467-475.
28.
Sun J, Ding J, Yue H, Xu B, Sodhi A, Xue K, et al. Hypoxia- induced BNIP3 facilitates the progression and metastasis of uveal melanoma by driving metabolic reprogramming. Autophagy 2024; 21: 191-209.
